In our study, nCRT combined with PD-L1 inhibitor therapy significantly enhanced the infiltration of immune cells, particularly CD8+ T cells and CD4+ T cells, into the TME, thus improving the therapeutic response in rectal cancer patients. Here, CD4 is linked to rectal cancer.